Physician profile
Robert J Marshall
NPI 1053365189
$15,031.86
in general payments reported to CMS, 2019-2025
35 companies · $931 in 2025
The $931 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $544 · 2021: $8,001 · 2022: $1,818 · 2023: $1,642 · 2024: $1,161 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,734.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,021.38 | 2021 | |
| Abbott Laboratories | $1,052.58 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $877.94 | 2019-2025 | Lifevest |
| Medtronic, INC. | $865.76 | 2021-2025 | Cobalt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Corevalve Evolut R |
| Pfizer INC. | $592.65 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $560.67 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $518.25 | 2019-2025 | |
| Amgen INC. | $440.32 | 2019-2025 | Repatha |
| Atricure, INC. | $350.18 | 2019-2022 | |
| Edwards Lifesciences Corporation | $346.74 | 2019-2024 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $336.08 | 2019-2023 | Brilinta, Farxiga |
| Novo Nordisk INC | $321.64 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $300.78 | 2021-2025 | Nexletol |
| Boston Scientific Corporation | $238.69 | 2019-2023 | Watchman |
| Heartflow, INC. | $158.84 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $149.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.41 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $108.43 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $107.10 | 2022 | |
| Abiomed | $78.45 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $72.62 | 2022-2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $72.21 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $68.13 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $45.96 | 2024 | Arcalyst |
| Corvista Health, INC. | $30.74 | 2025 | Corvista System |
| Amarin Pharma, INC. | $28.68 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $25.91 | 2023 | Austedo Xr |
| Angiodynamics, INC. | $24.10 | 2024 | Alphavac |
| Chiesi USA, INC. | $24.00 | 2024 | Juxtapid |
| Daiichi Sankyo INC. | $22.88 | 2024 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $19.76 | 2023 | Opsumit |
| Biotronik INC. | $16.96 | 2020 | |
| Lilly USA, LLC | $16.90 | 2025 | Mounjaro |
| Alnylam Pharmaceuticals INC. | $14.26 | 2023 | Amvuttra |
| Ge Healthcare | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.